SCHEMBL427733

SCHEMBL427733

Cc1nc2ccccc2c(C)c1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.57
ALDH1A1 P00352 7/20 0.52
CYP1A2 P05177 4/20 0.52
HSD17B10 Q99714 2/20 0.52
HPGD P15428 2/20 0.52
NUDT1 P36639 1/20 0.52
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
KDM4E B2RXH2 3/20 0.51
HTT P42858 2/20 0.51
PDE10A Q9Y233 1/20 0.50
MAPT P10636 5/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HCRTR1 O43613 1/20 0.49
LMNA P02545 1/20 0.49
THRB P10828 1/20 0.49
MAPK1 P28482 1/20 0.49
NPC1 O15118 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7453676 0.85 GPR3 (0.59) GPR3ALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL13943889 0.83 ALDH1A1 (0.49) GPR3ALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL28140128 0.83 GPR3 (0.57) GPR3ALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL231530 0.80 GPR3 (0.64) GPR3ALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL27920980 0.80 ALDH1A1 (0.46) GPR3ALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL28220555 0.80 ALDH1A1 (0.58) GPR3ALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL28220087 0.80 GPR3 (0.53) GPR3ALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL28142598 0.79 MAPT (0.55) GPR3ALDH1A1CYP1A2HSD17B10HPGD
Ammonia Solution, Strong SCHEMBL28822932 0.78 GPR3 (0.61) GPR3ALDH1A1CYP1A2HSD17B10HPGD
Hydrochloric Acid SCHEMBL27521191 0.78 GPR3 (0.61) GPR3ALDH1A1CYP1A2HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110248933-A Novel quinoline and isoquinoline derivatives for the treatment of pain and pain related disorders 埃斯特韦制药股份公司 2019-09-17 CN disclosed
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 GPR3 1096/4885ALDH1A1 3777/4885CYP1A2 140/4885
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 GPR3 1096/4885ALDH1A1 3777/4885CYP1A2 140/4885
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions XDH, CYP2D6, F12 GPR3 1096/4885ALDH1A1 3777/4885CYP1A2 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.